GLG News by Nexavar Prescribers for RCC: Oncologists (US)

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Microarrays and the fingerprints of cancer

July 10, 2011

How Bright Promise in Cancer Testing Fell Apart | www.nytimes.com

Genetic testing in regards too cancer cells has been a long time projectMicroaaray techniques using more reliable RNA versus DNA patterns will likely lead the wayProteionomic is is yet a further downstream approach to classifying cancer uniqueness

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Profitable palliation of none at all?

July 4, 2011

There is a plethora of new treatments for cancer.Universally new cancer treatments are very expensive.There are as many cancer patients being treated for palliative purposes as cure

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Avastin: a targeted drug without a target?

June 30, 2011

Breast Cancer Patients Plead for Avastin Approval | www.nytimes.com

Targeted cancer therapy is the trend in oncology therapyAvastin is a targeted therapy that has only theory backing up it's mode of actionAvastin has the benefit and drawback of being designated as broadly active yet specific to no cancer!

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Tarceva gives more proof: One should know the target for Targeted therapy

June 4, 2011

Roche’s Tarceva Stalls Lung Cancer With Gene Mutation in Late-Stage Study | www.bloomberg.com

So called targeted therapy has been a term coined over the last decade in the approach to treating cancer. A recent Roche study demonstrates almost doubling of disease control when one uses a patient population that has a defined target is treated with the drug Tarceva

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Necessity may be the mother of invention,but the father is profit.

April 16, 2011

Shortage Worsens of Leukemia Drug | online.wsj.com

There is a shortage of many cancer fighting medications, as more and more of the agents used to treat cancer become generic. The problem is both profit and regulation driven.

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Will provenge fall the way of radioimmunotherapy

November 19, 2010

Medicare Panel Supports Use of Provenge in FDA-Approved Population | blogs.wsj.com

Provenge recently approved for HRPC .Provenge was designed for asymptomatic patients with increasing PSAsProvenge involves referral to a specialized center to perform the procedure

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Herceptin's broader horizons

January 30, 2010

Roche gets EU approval for Herceptin to treat HER2-positive advanced stomach cancer | www.pharmabiz.com

There has been between a 20-30% Her over expression detected on adeno ca of gastric mucosaThe fastest growing esophageal malignancy is GE junction adenoca, which acts and is treated very similar to adeno ca of stomachOther solid tumors are likely to also demonstrate a similar benefit

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

New Cancer Target: PARP

December 16, 2009

BiPar Sciences' BSI-201 phase-3 trial makes progress in metastatic triple-negative breast cancer | www.pharmabiz.com

Recent evidence suggest that PARP is a new enzyme related target for TNBCTNBC sorely needs more effective therapyBe certain, the PARP target is not TNBC specific

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Gleevec move over for Tasigna

December 10, 2009

Novartis' Tasigna demonstrates greater efficacy over Glivec in chronic myeloid leukaemia | www.pharmabiz.com

Gleevec has revolutionized outcome/ therapy in CMLRecent phase III demonstrates better tolerance of Tasigna over GleevecCML outcome is reflected in MR and Tasigna seems to do it better

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Roche's Avastin declined by European "bean counters" for brain tumor

November 23, 2009

European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer | www.pipelinereview.com

Avastin utilized successfully in US for primary brain tumors, including the very aggressive GBMHealth care, including cancer, will be all about rationingRoche and other pharma companys better get ready for a rough future

Page : 12345678910Next1 to 10 of 124

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News